



(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2022/032791

(22) International Filing Date:
09 June 2022 (09.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/209,273 10 June 2021 (10.06.2021) US
63/275,427 03 November 2021 (03.11.2021) US

(71) Applicant: **INTELLIA THERAPEUTICS, INC.**
[US/US]; 40 Erie Street, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **MULEPATI, Sabin**; c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, Massachusetts 02139 (US). **PARMAR, Rubina Giare**; c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, Massachusetts 02139 (US). **STRETZ, Lindsey Jean**; c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, Massachusetts 02139 (US). **YOUNG, Michelle**; c/o Intellia Therapeutics, Inc., 40 Erie

Street, Cambridge, Massachusetts 02139 (US). **BONANNO, Jasmine Josephine**; c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge, Massachusetts 02139 (US).

(74) Agent: **BAUR, Amelia Feulner** et al.; McNeill Baur PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: MODIFIED GUIDE RNAS COMPRISING AN INTERNAL LINKER FOR GENE EDITING




Fig. 1A

(57) Abstract: This disclosure relates to modified guide RNAs comprising an internal linker for *in vitro* and *in vivo* gene editing methods.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*